Preclinical
This is the second IND to come out of the two companies’ collaboration. They will initiate a Phase I trial of the drug in cardiometabolic diseases.
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
The company says it plans to file an IND for the candidate, dubbed CFT8919, by the middle of next year.
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
This is after Larimar reported deaths in the highest dose levels of a nonhuman primate toxicology study.
Engine is ready to drive its lead program into clinical trials by 2023 while Giiant’s preclinical program will target moderate-to-severe ulcerative colitis.
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 25, 2021.
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
The Francis Crick Institute and the Latvian Institute of Organic Synthesis developed a new compound that blocks the life cycle of the mosquito-borne parasite that causes malaria.
PRESS RELEASES